Related Experiment Videos

Nude mouse models as predictors of chemotherapy in man: thymidine and pyrimidines

Bulletin Du Cancer
|January 1, 1979
PubMed

Insights

The National Cancer Institute

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Research

Background:

  • The National Cancer Institute reorganized its cancer treatment screening program.
  • A key feature is the use of human tumor xenografts in athymic mice.
  • This program aims to discover novel and effective anti-cancer agents.

Purpose of the Study:

  • To describe the new screening program and its prospective research questions.
  • To summarize existing data on clinically established antitumor drugs against human tumor xenografts.
  • To highlight promising compounds for clinical investigation based on xenograft model activity.

Main Methods:

  • Utilizing a panel of human tumors grown as xenografts in congenitally athymic mice.
  • Testing clinically established antitumor drugs for activity against these xenografts.
  • Investigating combination chemotherapy strategies, including high-dose thymidine and 5-fluorouracil with pyrimidine nucleosides.

Main Results:

  • High-dose thymidine demonstrated inhibition of human melanoma and teratocarcinoma growth in athymic mice.
  • Combination therapy with 5-fluorouracil and pyrimidine nucleosides (thymidine, uridine, cytidine) significantly augmented in vivo antitumor activity in murine models.
  • This suggests potential for enhanced efficacy in human tumor xenografts.

Conclusions:

  • The nude mouse xenograft model offers a broad range of investigations for cancer drug discovery.
  • Combination chemotherapy with pyrimidine nucleosides and 5-fluorouracil warrants further investigation for treating human tumors.
  • Aligning preclinical xenograft studies with clinical applications is crucial for developing new cancer therapies.

Related Concept Videos